Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Constance Delaby

Showing results (41-50 of 74) with videos related to

Pageof 8
Sort By:
Journal of Neurology, Neurosurgery, and Psychiatry|April 24, 2024
Clinical value of plasma ALZpath pTau217 immunoassay for assessing mild cognitive impairmentSylvain Lehmann, Susanna Schraen-Maschke, Jean-Sébastien Vidal, et al.
Journal of Neural Transmission (Vienna, Austria : 1996)|February 16, 2022
Blood amyloid and tau biomarkers as predictors of cerebrospinal fluid profilesConstance Delaby, Daniel Alcolea, Christophe Hirtz, et al.
Frontiers in Aging Neuroscience|June 13, 2018
Relevance of Aβ42/40 Ratio for Detection of Alzheimer Disease Pathology in Clinical Routine: The PLM<sub>R</sub> ScaleSylvain Lehmann, Constance Delaby, Guilaine Boursier, et al.
Molecular Neurodegeneration|October 8, 2024
Clarifying the association of CSF Aβ, tau, BACE1, and neurogranin with AT(N) stages in Alzheimer diseaseSylvain Lehmann, Susanna Schraen-Maschke, Luc Buée, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|August 5, 2024
Association of caffeine consumption with cerebrospinal fluid biomarkers in mild cognitive impairment and Alzheimer's disease: A BALTAZAR cohort studyDavid Blum, Emeline Cailliau, Hélène Béhal, et al.
Molecular Psychiatry|June 23, 2026
Beyond amyloid and tau: synaptic and neurodegenerative biomarkers shape MCI progressionConstance Delaby, Susanna Schraen-Maschke, Claire Paquet, et al.
Neurology|February 26, 2025
Comparative Performances of 4 Serum NfL Assays, pTau181, and GFAP in Patients With Amyotrophic Lateral SclerosisEtienne Mondesert, Constance Delaby, Elisa De La Cruz, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|October 30, 2025
Impact of preanalytical delay on the performance of plasma Aβ42, Aβ42/40, p-tau217, and p-tau217/Aβ42 in detecting brain amyloidosis in the ALZAN cohortConstance Delaby, Audrey Gabelle, Marie Duchiron, et al.
Ebiomedicine|June 13, 2025
Comparative performance of plasma pTau181/Aβ42, pTau217/Aβ42 ratios, and individual measurements in detecting brain amyloidosisSylvain Lehmann, Audrey Gabelle, Marie Duchiron, et al.
Medrxiv : the Preprint Server for Health Sciences|January 20, 2025
The ratio of plasma pTau217 to Aβ42 outperforms individual measurements in detecting brain amyloidosisSylvain Lehmann, Audrey Gabelle, Marie Duchiron, et al.
Pageof 8

Showing results (41-50 of 74) with videos related to

Sort By:
Pageof 8
Journal of Neurology, Neurosurgery, and Psychiatry|April 24, 2024
Clinical value of plasma ALZpath pTau217 immunoassay for assessing mild cognitive impairmentSylvain Lehmann, Susanna Schraen-Maschke, Jean-Sébastien Vidal, et al.
Journal of Neural Transmission (Vienna, Austria : 1996)|February 16, 2022
Blood amyloid and tau biomarkers as predictors of cerebrospinal fluid profilesConstance Delaby, Daniel Alcolea, Christophe Hirtz, et al.
Frontiers in Aging Neuroscience|June 13, 2018
Relevance of Aβ42/40 Ratio for Detection of Alzheimer Disease Pathology in Clinical Routine: The PLM<sub>R</sub> ScaleSylvain Lehmann, Constance Delaby, Guilaine Boursier, et al.
Molecular Neurodegeneration|October 8, 2024
Clarifying the association of CSF Aβ, tau, BACE1, and neurogranin with AT(N) stages in Alzheimer diseaseSylvain Lehmann, Susanna Schraen-Maschke, Luc Buée, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|August 5, 2024
Association of caffeine consumption with cerebrospinal fluid biomarkers in mild cognitive impairment and Alzheimer's disease: A BALTAZAR cohort studyDavid Blum, Emeline Cailliau, Hélène Béhal, et al.
Molecular Psychiatry|June 23, 2026
Beyond amyloid and tau: synaptic and neurodegenerative biomarkers shape MCI progressionConstance Delaby, Susanna Schraen-Maschke, Claire Paquet, et al.
Neurology|February 26, 2025
Comparative Performances of 4 Serum NfL Assays, pTau181, and GFAP in Patients With Amyotrophic Lateral SclerosisEtienne Mondesert, Constance Delaby, Elisa De La Cruz, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|October 30, 2025
Impact of preanalytical delay on the performance of plasma Aβ42, Aβ42/40, p-tau217, and p-tau217/Aβ42 in detecting brain amyloidosis in the ALZAN cohortConstance Delaby, Audrey Gabelle, Marie Duchiron, et al.
Ebiomedicine|June 13, 2025
Comparative performance of plasma pTau181/Aβ42, pTau217/Aβ42 ratios, and individual measurements in detecting brain amyloidosisSylvain Lehmann, Audrey Gabelle, Marie Duchiron, et al.
Medrxiv : the Preprint Server for Health Sciences|January 20, 2025
The ratio of plasma pTau217 to Aβ42 outperforms individual measurements in detecting brain amyloidosisSylvain Lehmann, Audrey Gabelle, Marie Duchiron, et al.
Pageof 8